Xuemin Zhang, Xintong Li, Shuang Song, Changhong Miao, Long Yan, Xiaolong Xu, Qingquan Liu
{"title":"揭示组织蛋白酶在慢性阻塞性肺疾病肺功能中的作用:孟德尔随机分析","authors":"Xuemin Zhang, Xintong Li, Shuang Song, Changhong Miao, Long Yan, Xiaolong Xu, Qingquan Liu","doi":"10.2147/COPD.S507283","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cathepsins are a group of proteases that can degrade the extracellular matrix of the lungs, leading to lung tissue destruction and remodeling in chronic obstructive pulmonary disease (COPD). However, the causal relationship between cathepsins and COPD remains unclear.</p><p><strong>Methods: </strong>We performed a two-sample Mendelian randomization (MR) analysis using genetic instruments for nine cathepsins (B, E, F, G, H, L2, O, S, and Z) and lung function measures (FVC, FEV1, FEV1/FVC, and PEF) in COPD. The MR analysis was conducted and reported as conducted and reported in accordance with the STROBE-MR Statement. We employed various MR methods and conducted sensitivity analyses to validate the results.</p><p><strong>Results: </strong>We found a significant association of cathepsin B with PEF (IVW beta = 0.016, 95% CI = 0.007 to 0.024, P = 2.83E-4), the FEV1/FVC ratio (IVW beta = 0.014, 95% CI = 0.004 to 0.023, P = 0.004), and FEV1 (IVW beta = 0.010, 95% CI = 0.002 to 0.018, P = 0.012) in COPD. These associations were consistent across different MR methods and robust to pleiotropy and heterogeneity. Multivariate MR analysis confirmed the independent effect of cathepsin B on lung function after adjusting for other cathepsins. Reverse MR analysis and colocalization analysis showed no evidence of reverse causality or shared genetic pathways with smoking.</p><p><strong>Conclusion: </strong>Our study suggested that elevated cathepsin B levels may reduce the risk of lung function decline in COPD. Targeting cathepsin B and its inhibitors could be a potential therapeutic strategy for COPD. Reduced serum levels of cathepsin B may serve as a biomarker of progressive decline in lung function in patients with COPD. However, further studies are needed to elucidate the underlying mechanisms and clinical implications of these findings.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1819-1828"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153959/pdf/","citationCount":"0","resultStr":"{\"title\":\"Unveiling the Role of Cathepsins on Lung Function in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Analysis.\",\"authors\":\"Xuemin Zhang, Xintong Li, Shuang Song, Changhong Miao, Long Yan, Xiaolong Xu, Qingquan Liu\",\"doi\":\"10.2147/COPD.S507283\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cathepsins are a group of proteases that can degrade the extracellular matrix of the lungs, leading to lung tissue destruction and remodeling in chronic obstructive pulmonary disease (COPD). However, the causal relationship between cathepsins and COPD remains unclear.</p><p><strong>Methods: </strong>We performed a two-sample Mendelian randomization (MR) analysis using genetic instruments for nine cathepsins (B, E, F, G, H, L2, O, S, and Z) and lung function measures (FVC, FEV1, FEV1/FVC, and PEF) in COPD. The MR analysis was conducted and reported as conducted and reported in accordance with the STROBE-MR Statement. We employed various MR methods and conducted sensitivity analyses to validate the results.</p><p><strong>Results: </strong>We found a significant association of cathepsin B with PEF (IVW beta = 0.016, 95% CI = 0.007 to 0.024, P = 2.83E-4), the FEV1/FVC ratio (IVW beta = 0.014, 95% CI = 0.004 to 0.023, P = 0.004), and FEV1 (IVW beta = 0.010, 95% CI = 0.002 to 0.018, P = 0.012) in COPD. These associations were consistent across different MR methods and robust to pleiotropy and heterogeneity. Multivariate MR analysis confirmed the independent effect of cathepsin B on lung function after adjusting for other cathepsins. Reverse MR analysis and colocalization analysis showed no evidence of reverse causality or shared genetic pathways with smoking.</p><p><strong>Conclusion: </strong>Our study suggested that elevated cathepsin B levels may reduce the risk of lung function decline in COPD. Targeting cathepsin B and its inhibitors could be a potential therapeutic strategy for COPD. Reduced serum levels of cathepsin B may serve as a biomarker of progressive decline in lung function in patients with COPD. However, further studies are needed to elucidate the underlying mechanisms and clinical implications of these findings.</p>\",\"PeriodicalId\":48818,\"journal\":{\"name\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"volume\":\"20 \",\"pages\":\"1819-1828\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153959/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/COPD.S507283\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S507283","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
背景:组织蛋白酶是一组蛋白酶,可降解肺细胞外基质,导致慢性阻塞性肺疾病(COPD)肺组织破坏和重塑。然而,组织蛋白酶与COPD之间的因果关系尚不清楚。方法:我们使用遗传仪器对COPD患者的9种组织蛋白酶(B、E、F、G、H、L2、O、S和Z)和肺功能测量(FVC、FEV1、FEV1/FVC和PEF)进行了两样本孟德尔随机化(MR)分析。按照STROBE-MR声明进行MR分析并报告。我们采用了不同的MR方法,并进行了敏感性分析来验证结果。结果:我们发现组织蛋白酶B与COPD患者的PEF (IVW β = 0.016, 95% CI = 0.007 ~ 0.024, P = 2.83E-4)、FEV1/FVC比值(IVW β = 0.014, 95% CI = 0.004 ~ 0.023, P = 0.004)和FEV1 (IVW β = 0.010, 95% CI = 0.002 ~ 0.018, P = 0.012)有显著相关性。这些关联在不同的MR方法中是一致的,并且对多效性和异质性是稳健的。多变量磁共振分析证实了组织蛋白酶B在调整其他组织蛋白酶后对肺功能的独立影响。反向磁共振分析和共定位分析显示没有证据表明与吸烟有反向因果关系或共同的遗传途径。结论:本研究提示组织蛋白酶B水平升高可降低COPD患者肺功能下降的风险。靶向组织蛋白酶B及其抑制剂可能是COPD的潜在治疗策略。血清组织蛋白酶B水平降低可作为COPD患者肺功能进行性下降的生物标志物。然而,需要进一步的研究来阐明这些发现的潜在机制和临床意义。
Unveiling the Role of Cathepsins on Lung Function in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Analysis.
Background: Cathepsins are a group of proteases that can degrade the extracellular matrix of the lungs, leading to lung tissue destruction and remodeling in chronic obstructive pulmonary disease (COPD). However, the causal relationship between cathepsins and COPD remains unclear.
Methods: We performed a two-sample Mendelian randomization (MR) analysis using genetic instruments for nine cathepsins (B, E, F, G, H, L2, O, S, and Z) and lung function measures (FVC, FEV1, FEV1/FVC, and PEF) in COPD. The MR analysis was conducted and reported as conducted and reported in accordance with the STROBE-MR Statement. We employed various MR methods and conducted sensitivity analyses to validate the results.
Results: We found a significant association of cathepsin B with PEF (IVW beta = 0.016, 95% CI = 0.007 to 0.024, P = 2.83E-4), the FEV1/FVC ratio (IVW beta = 0.014, 95% CI = 0.004 to 0.023, P = 0.004), and FEV1 (IVW beta = 0.010, 95% CI = 0.002 to 0.018, P = 0.012) in COPD. These associations were consistent across different MR methods and robust to pleiotropy and heterogeneity. Multivariate MR analysis confirmed the independent effect of cathepsin B on lung function after adjusting for other cathepsins. Reverse MR analysis and colocalization analysis showed no evidence of reverse causality or shared genetic pathways with smoking.
Conclusion: Our study suggested that elevated cathepsin B levels may reduce the risk of lung function decline in COPD. Targeting cathepsin B and its inhibitors could be a potential therapeutic strategy for COPD. Reduced serum levels of cathepsin B may serve as a biomarker of progressive decline in lung function in patients with COPD. However, further studies are needed to elucidate the underlying mechanisms and clinical implications of these findings.
期刊介绍:
An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals